September 4, 2019

Dr. Stephen Goutman Develops New Way to Measure ALS Clinical Trial Success

Dr. Stephen Goutman has developed a new clinical rating scale for ALS, which can be used in drug trials to measure disease progression.

Stephen Goutman, M,D., M.S. Portrait
Stephen Goutman, M.D., M.S.

Associate Professor and Director of the Multidisciplinary ALS Clinic, Dr. Stephen Goutman, has developed a new clinical rating scale for ALS, which can be used in drug trials to measure disease progression. This scale combines measures of patient function with survival and is known as ALS/SURV. ALS/SURV is a major advance in the field of ALS and will likely accelerate clinical trials and drug discovery for ALS.

This work was recently published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and can be found HERE.